Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight key points from the study, noting the specific activators like L-serine and their dosages. Phrases such as 'huge improvement' and 'very promising results' demonstrate an excited tone surrounding the research. Comments on the article's potential impact, like its comparison to previous treatment methods, show how the choice of words conveys hope in advancing Alzheimer’s research.
Many discussions express support for the findings of the publication, sharing enthusiasm about the potential for combined metabolic activators.
There is a strong curiosity among participants, as evidenced by frequent references to the study's results and methodology.
While many posts summarize the study, some users dive deeper into the specific components and their implications for treatment.
The sentiment indicates that the study is perceived as having a significant influence on Alzheimer’s treatment discussions.
Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carnitine. Really should be front page news. https://t.co/TmUhR1HE09
New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/jTmegtY0Ws
Here's the full study: https://t.co/af2Or769RX Randomized, placebo-controlled clinical trial... Participants in the treatment arm received: 2.35 g L-serine 1 g nicotinamide riboside 2.55 g N-acetyl-L-cysteine 3.73 g L-carnitine tartrate Once a day for 28 d, then twice a day.
代謝活性化剤の併用はアルツハイマー病患者の認知機能を改善する：無作為化二重盲検プラセボ対照第II相試験 2023 https://t.co/RVgRKa5Auk 代謝活性化剤（CMA）と用量 L-セリン 12.35g ニコチンアミドリボシド 1g N-アセチル-L-システイン 2.55g L-カルニチン酒石酸塩 3.73g
Improving energetics led to improved cognitive function, hippocampal volumes, and cortical thickness. We’d still recommend reducing immune activation and its cause(s) for success in the long-term, but this could be a good short-term therapeutic. https://t.co/1hGSQLuboL https://t.co/BuvWVe8snr
Small study (n=69), but @Mardinoglu et al report combined metabolic activators improve cognitive functions in a Phase 2 trial of #Alzheimers (NCT04044131 - which also involved #Parkinsons participants, but no mention in this report; Maybe that comes next?) https://t.co/spU26OYa8v https://t.co/ioU7Wi5GtK
A new study reveals a significant improvement in cognitive abilities of Alzheimer's patients using combined metabolic activators. This phase-II trial demonstrated enhanced cognitive scores and changes in brain imaging…
Alzheimer's disease is linked to metabolic issues. This video discusses a phase-II clinical trial that tested combined metabolic activators against a placebo. The trial focused on cognitive function improvement and…
This video delves into the foundational concepts of quantum mechanics. We explore wave-particle duality, quantum entanglement, and the implications for modern physics. Join us as we unravel the complexities of this…
Wygląda na to że zaczynamy rozumieć chorobę Alzhaimera https://t.co/OXfTut5Mad
https://t.co/kZaHL5jys1
https://t.co/bEZagCL9AB
RT @Alzhacker: 代謝活性化剤の併用はアルツハイマー病患者の認知機能を改善する：無作為化二重盲検プラセボ対照第II相試験 2023 https://t.co/RVgRKa5Auk 代謝活性化剤（CMA）と用量 L-セリン 12.35g ニコチンアミドリボシド 1g…
RT @Alzhacker: 代謝活性化剤の併用はアルツハイマー病患者の認知機能を改善する：無作為化二重盲検プラセボ対照第II相試験 2023 https://t.co/RVgRKa5Auk 代謝活性化剤（CMA）と用量 L-セリン 12.35g ニコチンアミドリボシド 1g…
RT @Alzhacker: 代謝活性化剤の併用はアルツハイマー病患者の認知機能を改善する：無作為化二重盲検プラセボ対照第II相試験 2023 https://t.co/RVgRKa5Auk 代謝活性化剤（CMA）と用量 L-セリン 12.35g ニコチンアミドリボシド 1g…
RT @Alzhacker: 代謝活性化剤の併用はアルツハイマー病患者の認知機能を改善する：無作為化二重盲検プラセボ対照第II相試験 2023 https://t.co/RVgRKa5Auk 代謝活性化剤（CMA）と用量 L-セリン 12.35g ニコチンアミドリボシド 1g…
RT @Alzhacker: 代謝活性化剤の併用はアルツハイマー病患者の認知機能を改善する：無作為化二重盲検プラセボ対照第II相試験 2023 https://t.co/RVgRKa5Auk 代謝活性化剤（CMA）と用量 L-セリン 12.35g ニコチンアミドリボシド 1g…
代謝活性化剤の併用はアルツハイマー病患者の認知機能を改善する：無作為化二重盲検プラセボ対照第II相試験 2023 https://t.co/RVgRKa5Auk 代謝活性化剤（CMA）と用量 L-セリン 12.35g ニコチンアミドリボシド 1g N-アセチル-L-システイン 2.55g L-カルニチン酒石酸塩 3.73g
補充GlyNAC保護線粒體功能、逆轉衰老、延長壽命 https://t.co/UBfQh65qRl 來自 @YouTube
@PaulSkallas @mindslikeseeds @Geopolymeric https://t.co/Yyd3dIDOmo There are other interesting studies on causes and treatments behind amyloid plaque theories. It is better to try, than listening to high tier science
@Mangan150 https://t.co/19TP6xcRoo
@DavidPerlmutter This is an interesting study! https://t.co/3yVx8RpNDG
@drjkahn https://t.co/5DiNmI4W8y
RT @mike_lustgarten: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinde…
RT @mike_lustgarten: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinde…
RT @mike_lustgarten: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinde…
RT @mike_lustgarten: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinde…
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/JysWyywTXc
RT @frankyap222: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, p…
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/HL446xOejZ https://t.co/MaTk9GmTbr
Found this research report on the treatment of Alzheimer's Disease quite interesting. Researchers from 7 different universities in Turkey, Sweden and the UK. This isn't medical advice: do your own homework. https://t.co/Wpr9eQVRGh
Supplements to help dementia: New Study: 29% Improvement In Alzheimer’s Disease?! https://t.co/kMMHO8muEL via @YouTube
RT @DrDaleBredesen: Improving energetics led to improved cognitive function, hippocampal volumes, and cortical thickness. We’d still recomm…
RT @DrDaleBredesen: Improving energetics led to improved cognitive function, hippocampal volumes, and cortical thickness. We’d still recomm…
RT @DrDaleBredesen: Improving energetics led to improved cognitive function, hippocampal volumes, and cortical thickness. We’d still recomm…
RT @DrDaleBredesen: Improving energetics led to improved cognitive function, hippocampal volumes, and cortical thickness. We’d still recomm…
RT @DrDaleBredesen: Improving energetics led to improved cognitive function, hippocampal volumes, and cortical thickness. We’d still recomm…
Improving energetics led to improved cognitive function, hippocampal volumes, and cortical thickness. We’d still recommend reducing immune activation and its cause(s) for success in the long-term, but this could be a good short-term therapeutic. https://t.co/1hGSQLuboL https://t.co/BuvWVe8snr
https://t.co/IWlDsa8LAL #GlyNACandNACplus
@angryhacademic Serine keeps the TCA cycle going even in hypoxia. https://t.co/r3hfAlqlfh https://t.co/TCtEYHQ9yl "12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%)."
RT @varsanot: Translational #Neurodegeneration, Jan 2023 Olink Proteomics analysis helps confirm drug response/efficacy in an Alzheimer’s d…
Translational #Neurodegeneration, Jan 2023 Olink Proteomics analysis helps confirm drug response/efficacy in an Alzheimer’s disease (AD) phase-II clinical trial! A comprehensive plasma #metabolome and #proteome analysis was used to…https://t.co/UBw8lFVlcq https://t.co/e8Pb7dNbBp
Ativadores do metabolismo mostram efeitos interessantes no Alzheimer L-serine 12.35 g Nicotinamide riboside 1g N-acetyl-L-cysteine 2.55g L-carnitine tartrate 3.73g Lembrando que a maioria das doenças neurodegenerativas tem cunho metabólico em sua origem https://t.co/Caxjle8mZy
RT @renesugar: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, pla…
RT @renesugar: https://t.co/TCtEYHQ9yl "AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily bet…
RT @renesugar: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, pla…
RT @renesugar: https://t.co/TCtEYHQ9yl "One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L…
RT @renesugar: https://t.co/TCtEYHQ9yl "One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L…
RT @renesugar: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, pla…
治療阿爾茨海默氏症 https://t.co/roXyrIdnRy 来自 @YouTube https://t.co/mjbWGIyIXg
治療阿爾茨海默氏症 https://t.co/roXyrIdnRy 来自 @YouTube
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
New Study: 29% Improvement In Alzheimer’s Disease?! https://t.co/1iyeeSQBKh via @YouTube
@chydorina @remissionbiome You might find this paper interesting. https://t.co/D4jLKH500A
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
Fantastic results. https://t.co/CroqacZGrq
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
RT @renesugar: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, pla…
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
RT @GeneticLifehack: Here's the full study: https://t.co/af2Or769RX Randomized, placebo-controlled clinical trial... Participants in the…
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
RT @erogul1: Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carniti…
Huge improvement of cognitive function in Alzheimer’s patients using cocktail of 4 OTC supplements: serine, NR, NAC, L-carnitine. Really should be front page news. https://t.co/TmUhR1HE09
9/ Here's the link again - read it for yourself: https://t.co/af2Or769RX Perhaps it will turn out to be a nothingburger in larger trials
Here's the full study: https://t.co/af2Or769RX Randomized, placebo-controlled clinical trial... Participants in the treatment arm received: 2.35 g L-serine 1 g nicotinamide riboside 2.55 g N-acetyl-L-cysteine 3.73 g L-carnitine tartrate Once a day for 28 d, then twice a day.
RT @BradStanfieldMD: References: https://t.co/5R2aFne2oX https://t.co/SDtRvPeVcL https://t.co/Gt2L147oTV
This 4 drug combo treatment, consisting of L-serine, NR, NAC & L-carnitine, improved ADAS-cog scores and brain metabolite profiles in Alzheimer's disease. In addition, NAD+ and glutathione levels were improved and hippocampal volume was maintained. https://t.co/a3xUqdsv1g
RT @renesugar: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, pla…
RT @renesugar: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, pla…
RT @RaisingNad: New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised…
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/hc058bFc5u
Alzheimer's clinical trial using l-serine, nicotinamide riboside, NAC, and L-carnitine. Very promising results! I hope they do further and larger trials on this. https://t.co/af2Or769RX #alzheimers
https://t.co/TCtEYHQ9yl "AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84."
https://t.co/TCtEYHQ9yl "One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%)."
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/TCtEYHQ9yl
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
@RaisingNad https://t.co/C3xD4K7KTh
https://t.co/C3xD4K7KTh
RT @Parsifaler: CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, prot…
RT @transhumanismAU: New Study: 29% Improvement In Alzheimer’s Disease?! https://t.co/vZqzZvq4zb via @BradStanfieldMD
RT @HealthOverhaul: 5. The article 29% improvement VS 12% in placebo. Combined metabolic activators improve cognitive functions in Alzhei…
RT @HealthOverhaul: 5. The article 29% improvement VS 12% in placebo. Combined metabolic activators improve cognitive functions in Alzhei…
RT @HealthOverhaul: 5. The article 29% improvement VS 12% in placebo. Combined metabolic activators improve cognitive functions in Alzhei…
RT @HealthOverhaul: 5. The article 29% improvement VS 12% in placebo. Combined metabolic activators improve cognitive functions in Alzhei…
RT @HealthOverhaul: 5. The article 29% improvement VS 12% in placebo. Combined metabolic activators improve cognitive functions in Alzhei…
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial | Translational Neurodegeneration | Full Text https://t.co/OPipg6okdp
New Study: 29% Improvement In Alzheimer’s Disease?! https://t.co/vZqzZvq4zb via @BradStanfieldMD
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/VIZQD1eUre
Treating Alzheimer's Disease patients with combined metabolic activators has a positive effect on cognitive function and markers of metabolic abnormalities, finds a study published in Translational Neurodegeneration. https://t.co/o5jNFaY4FA
https://t.co/014V3zUkPw New Study: 29% Improvement In Alzheimer’s Disease?!
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. https://t.co/vEqVRAzvWe
5. The article 29% improvement VS 12% in placebo. Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/9IsMibaWz6
References: https://t.co/5R2aFne2oX https://t.co/SDtRvPeVcL https://t.co/Gt2L147oTV
https://t.co/TElqcyiMor
RT @hernangraffe: https://t.co/Tw8Vx5WWg8
https://t.co/Tw8Vx5WWg8
Rx severe Alzheimer’s ? Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/X1ZFj4Unl0
RT @ScienceofPD: Small study (n=69), but @Mardinoglu et al report combined metabolic activators improve cognitive functions in a Phase 2 tr…
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/AkwhTy6UAm
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
Trend top+13: Yulug B, ..., Mardinoglu A (Transl Neurodegener) __Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial__ https://t.co/LzPh8vQCCX
RT @ScienceofPD: Small study (n=69), but @Mardinoglu et al report combined metabolic activators improve cognitive functions in a Phase 2 tr…
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II t... https://t.co/DNjF5L2KTj
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
Small study (n=69), but @Mardinoglu et al report combined metabolic activators improve cognitive functions in a Phase 2 trial of #Alzheimers (NCT04044131 - which also involved #Parkinsons participants, but no mention in this report; Maybe that comes next?) https://t.co/spU26OYa8v https://t.co/ioU7Wi5GtK
CMA has positive effects on cognitive functions and markers of metabolic abnormalities, especially in patients with severe AD; CMA:L-serine, nicotinamide riboside, N-acetyl-L-cysteine & L-carnitine tartrate https://t.co/ZvU0rD4qKn
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @agingdoc1: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, pla…
https://t.co/TCtEYHQ9yl "AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84."
https://t.co/TCtEYHQ9yl "One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%)."
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/TCtEYHQ9yl
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @agingdoc1: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, pla…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
https://t.co/Tw8Vx5WWg8
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%). https://t.co/AnyYmnejuy
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @Parsifaler: CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, prot…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @Parsifaler: CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, prot…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @agingdoc1: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, pla…
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/9eqimK9JAK https://t.co/dpUOVNFelN
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
@elonmusk If you won't get serious about biotech, at least do the minimum to delay dementia... we have plenty of senile people in power already ;) https://t.co/3EMzWlWXeZ
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @BradStanfieldMD: Wow, I need to go through this in more detail but a new human, randomised, double-blinded, placebo-controlled trial of…
RT @Parsifaler: CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, prot…
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients. https://t.co/8mks9H5yoB
RT @RaisingNad: New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised…
@JuliaB_fitness @jacobmhands @foundmyfitness @DrMorganLevine @rhg_1 @onelifemax @ConsumerLab after reading this paper https://t.co/Oedo093hVY, I think I am going to get some l-carnitine tartrate, they said it's the best form for fat burning, the dose seems huge, 3.75g per day, I am eating lots of meat daily, but contains only 200mg per 8oz, nowhere close to the dose
RT @BWalkerTTAGGG: Finally, a success against Alzheimer's. But it's unpatented molecules so it's "not news"... https://t.co/rvxyo0dY2G
RT @RaisingNad: New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised…
RT @BWalkerTTAGGG: Finally, a success against Alzheimer's. But it's unpatented molecules so it's "not news"... https://t.co/rvxyo0dY2G
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial - PubMed https://t.co/OZQw6glBmv
RT @RaisingNad: New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised…
https://t.co/xFJv88AcEp
@JohnBarnesSF Was it really Groundhog Day, or is it just a memory issue? https://t.co/rvxyo0dY2G
@DarthPutinKGB Has the master strategist considered anti-dementia therapy? (This could apply equally to Trump, Biden, etc....) https://t.co/rvxyo0dY2G
@EleanorSheekey Don't want to distract you from senolytics... but look, successful Alzheimer's trial: https://t.co/rvxyo0dY2G
@lukasauperl @adamgries @davidasinclair https://t.co/rvxyo0dY2G
@adamgries And when there ARE successful trials vs. diseases of aging, they go down the memory hole: https://t.co/rvxyo0dY2G
@ZachWeiner Occam's Razor... both Dorsey and Musk hate you. No problem, just avoid dementia until they are gone (yes, yet another human trial you won't read): https://t.co/rvxyo0dY2G
@HobbesCaltous @CyberGameway @EKSAtech @MVGCharity @ASUS Successful anti-Alzheimer's trial. Any chance you'll notice? https://t.co/rvxyo0dY2G
@CharlesMBrenner Meanwhile, back on the Gulag, a successful anti-Alzheimer's study goes down the memory hole. https://t.co/rvxyo0dY2G
@alzheimerssoc @RishiSunak @arlenephillips @Vicky_McClure @KateLeeCEO @Debbie_abrahams There are treatments that work. But you won't get them from Number 10. https://t.co/rvxyo0dY2G
Finally, a success against Alzheimer's. But it's unpatented molecules so it's "not news"... https://t.co/rvxyo0dY2G
RT @RaisingNad: New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised…
RT @RaisingNad: New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised…
RT @RaisingNad: New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised…
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial - PubMed https://t.co/IAal7UH056
New: Combined metabolic activators (including NR) improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial https://t.co/jTmegtY0Ws
RT @ad_papers: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, pla…
RT @Metabbot: Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, plac…
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener #metabolomics https://t.co/nBMWAaBz7o
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Transl Neurodegener #Alzheimers https://t.co/MrdYG0RhkE
Combined metabolic activators improve cognitive functions in alzheimer's disease patients: a randomised, double-blinded, pla... - Yulug B et al. - https://t.co/xw7wITf6ry #microbiome
補充GlyNAC保護線粒體功能、逆轉衰老、延長壽命 https://t.co/eLj4ucCDeU 来自 @YouTube